Significance of cell kinetic parameters in the prognosis of malignant melanoma: A review

Journal of Cutaneous Pathology

Volumn 34, Issue 2, 2007, Pages 139-145

  Vereecken, Pierre ^a,b,c,d   Laporte, Marianne ^a   Heenen, Michel ^a  

^a ERASME HOSPITAL   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^d NONE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; KI 67 ANTIGEN;

ANAPHASE; APOPTOSIS; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL KINETICS; CELL LABELING; CELL LOSS; CYTOPATHOLOGY; DNA SYNTHESIS; HUMAN; IN SITU HYBRIDIZATION; MELANOMA; METAPHASE; MITOSIS INDEX; PROGNOSIS; PROPHASE; REVIEW; SKIN BIOPSY; TELOPHASE; TISSUE SECTION;

CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; KI-67 ANTIGEN; KINETICS; MELANOMA; MITOTIC INDEX; SKIN NEOPLASMS;

EID: 33846439800     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2006.00588.x     Document Type: Review

References (64)

1. Ostmeier H, Fuchs B, Otto F et al. Prognostic immunohistochemical markers of primary human melanomas. Br J Dermatol 2001; 145: 203.
2. Michels JJ, Marnay J, Delozier T, Denoux Y, Chasle J. Proliferative activity in primary breast carcinomas is a salient prognostic factor. Cancer 2004; 100: 455.
3. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004; 57: 675.
4. Miettinen M, El-Rifai WHL, Sobin L, Lasota J. Evaluation of malignancy and prognosis of gastro-intestinal stromal tumours: a review. Hum Pathol 2002; 33: 478.
5. Wright N. The theory of renewing cell populations. In: Wright, N, Alison, M, eds. Pathology of epithelial cell populations. Oxford: Clarendon Press, 1984; 21.
6. Heenen M, Achten G, Galand P. Autoradiographic analysis of cell kinetics in human normal epidermis and basal cell carcinoma. Cancer Res 1973; 33: 123.
7. Heenen M, Lambert JC, Achten G, Galand P. Kinetics of cell proliferation in benign and premalignant tumours of the human skin. J Natl Cancer Inst 1975; 54: 825.
8. Burford-Mason AP, MacKay AJ, Cummins M, Dardick I. Detection of proliferating cell nuclear antigen in paraffin-embedded specimens is dependent on preembedding tissue handling. Arch Pathol Lab Med 1994; 118: 1007.
9. Maga G, Hübscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 2003; 116: 3051.
10. Woosley JT, Dietrich DR. Prognostic significance of PCNA grade in malignant melanoma. J Cutan Pathol 1993; 20: 498.
11. Evans AT, Blessing K, Orrell JM, Grant A. Mitotic indices, anti-PCNA immunostaining, and AgNORs in thick cutaneous melanoma displaying paradoxical behaviour. J Pathol 1992; 168: 15.
12. Ghazvini S, Kroll S, Char DH, Frigillana H. Comparative analysis of proliferating cell nuclear antigen, bromodeoxyuridine, and mitotic index in uveal melanoma. Invest Ophthalmol Vis Sci 1995; 36: 2762.
13. Mooney EE, Ruis Peris JM, O'Neill A, Sweeney EC. Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J Clin Pathol 1995; 48: 242.
14. Laporte M, Galand P, Fokan D, De Graef C, Heenen M. Apoptosis in established and healing psoriasis. Dermatology 2000; 200: 314.
15. Tannapfel A, Geissler F, Kockerling F, Katalinic A, Hauss J, Wittekind C. Apoptosis and proliferation in relation to histopathological variables and prognosis in hepatocellular carcinoma. J Pathol 1999; 187: 439.
16. Hagedorn HG, Tubel J, Wiest I, Nerlich AG. In situ apoptotic and proliferation index in laryngeal squamous cell carcinomas. Anal Cell Pathol 1998; 16: 177.
17. Shimazaki K, Ohshima K, Suzumiya J, Kawasaki C, Kikuchi M. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. Br J Haematol 2000; 110: 584.
18. Donhuijsen K, Schmidt U, Hirche H, Van Beuningen D, Burdach V. Changes in the mitotic rate and cell cycle fractions caused by delayed fixation. Hum Pathol 1990; 21: 709.
19. Baak JP. Mitosis counting in tumours. Human Pathol 1990; 21: 683.
20. Baak JP, Van Dop H, Kurver PH, Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985; 56: 374.
21. Lindboe CF, Torp SH. Comparison of Ki-67 equivalent antibodies. J Clin Pathol 2002; 55: 467.
22. Hofman-Wellenhof R, Smolle J, Kerl H. The influence of staining procedures on the assessment of cell proliferation as defined by the monoclonal antibody Ki-67. Am J Dermatopathol 1990; 12: 458.
23. Heuschmid M, Hofmockel G, Dexler B, Dammrich J, Bassukas ID. Different antigen unmasking techniques lead to significant differences in immunohistochemical staining of Ki-67 (Mib-1) in renal carcinomas. Oncol Rep 2002; 9: 19.
24. Woosley JT. Measuring cell proliferation. Arch Pathol Laboratory Med 1991; 115: 555.
25. van Diest PJ, Baak JP, Matze-Cok P et al. Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the multicenter morphometric mammary carcinoma project. Hum Pathol 1992; 23: 603.
26. Clark WH Jr, Elder DE, Guerry D IV et al. Model predicting survival in stage I melanoma based on tumour progression. J Natl Cancer Inst 1989; 81: 1893.
27. Barnhill RL, Katzen J, Spatz A, Fine J, Berwick M. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol 2005; 32: 268.
28. Nagore E, Oliver V, Botella-Estrada R, Morena-Picot S, Insa A, Fortea JM. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. Melanoma Res 2005; 15: 169.
29. Gimotty PA, Guerry D, Ming ME et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer Staging. J Clin Oncol 2004; 22: 3668.
30. Busam KJ, Mujumdar U, Hummer AJ et al. Cutaneous desmoplastic melanoma: reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol 2004; 28: 1518.
31. Francken AB, Shaw HM, Thompson JF et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow up. Ann Surg Oncol 2004; 11: 426.
32. Azzola MF, Shaw HM, Thompson JF et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003; 97: 1488.
33. Retsas S, Henry K, Mohammed MQ, MacRae K. Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. Eur J Cancer 2002; 38: 511.
34. Schmid-Wendtner MH, Baumert J, Schmidt M, Plewig G, Volkenandt J, Holzel D. Prognostic index for cutaneous melanoma. an analysis after follow-up of 2715 patients. Melanoma Res 2001; 11: 619.
35. Frahm SO, Schubert C, Parwaresch R, Rudolph P. High proliferative activity may predict early metastasis of thin melanomas. Hum Pathol 2001; 32: 1376.
36. Ostmeier H, Fuchs B, Otto F et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer 1999; 85: 2391.
37. Spatz A, Shaw HM, Crotty KA, Thompson JF, McCarthy SW. Analysis of histopathological factors associated with prolonged survival of 10 years or more for patients with thick melanomas (>5 mm). Histopathology 1998; 33: 406.
38. Quinn MJ, Crotty KA, Thompson JF, Coates AS, O'Brien CJ, McCarthy WH. Desmoplastic and desmoplastic neurotropic melanoma. Experience with 280 patients. Cancer 1998; 83: 1128.
39. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 1996; 78: 427.
40. Smolle J, Soyer HP, Kerl H. Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody. A quantitative immunohistochemical study. Am J Dermatopathol 1989; 11: 301.
41. Kuhnl-Petzold C, Keil H, Schopf E. Effect of mitotic density on the probability of survival of patients with thin (less or equal to 1.5 mm) melanomas. Z Hautkr 1986; 61: 15.
42. Sondak VK, Taylor JM, Sabel MS et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004; 11: 247.
43. Kesmodel SB, Karakousis GC, Botbyl JD et al. Mitotic rate as a predictor of sentinel node positivity in patients with thin melanomas. Ann Surg Oncol 2005; 12: 449.
44. Schmoeckel C, Braun-Falco O. Prognostic index in malignant melanoma. Arch Dermatol 1978; 114: 871.
45. Hazan C, Melzer K, Panageas KS et al. Evaluation of the proliferation marker MIB-1 in the prognosis of cutaneous malignant melanoma. Cancer 2002; 95: 634.
46. Moretti S, Spallanzani A, Chiarugi A, Fabiani M, Pinzi C. Correlation of Ki-67 expression in cutaneous primary melanoma with prognosis in a prospective study: different correlation according to thickness. J Am Acad Dermatol 2001; 44: 188.
47. Henrique R, Azevedo R, Bento MJ, Domingues JC, Silva C, Jeronimo C. Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma. J Am Acad Dermatol 2000; 43: 991.
48. Sparrow LE, English DR, Taran JM, Heenan PJ. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors. Am J Dermatopathol 1998; 20: 12.
49. Vogt T, Zipperer KH, Vogt A, Holzel D, Landthaler M, Stolz W. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology 1997; 30: 57.
50. Talve LA, Collan YU, Ekfors TO. Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of malignant melanomas of the skin. J Cutan Pathol 1996; 23: 335.
51. Böni R, Doguoglu A, Burg G, Muller B, Dummer R. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. J Am Acad Dermatol 1996; 35: 416.
52. Ramsay JA, From L, Iscoe NA, Kahn HJ. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol 1995; 105: 22.
53. van Oijen MG, Medema RH, Slootweg PJ, Rijksen G. Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol 1998; 110: 24.
54. Rajagopalan H, Lengauer C. Aneuploidy and cancer. Nature 2004; 432: 338.
55. Pilch H, Gunzel S, Schaffer U, Tanner B, Heine M. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging. Cancer 2000; 88: 1370.
56. Korabiowska M, Brinck U, Kotthaus I, Berger H, Droese M. Analysis of the DNA content in the progression of recurrent and metastatic melanomas. Anticancer Res 2000; 20: 2791.
57. Korabiowska M, Brinck U, Brinkmann U, Kotthaus I, Berger H, Droese M. Prognostic significance of newly defined ploidy related parameters in melanoma. Anticancer Res 2000; 20: 1685.
58. Dooley WC, Allison DC, Lin P, Paul M. Evidence for altered cell-cycle traverse of the non-modal cells of the heteroploid MCa-11 line. Cell Prolif 1993; 26: 349.
59. Graves JA, McMillan J. Control of DNA synthesis in polyploid mammalian cells. J Cell Physiol 1984; 121: 409.
60. Fujikawa-Yamamoto K, Wang S, Yamagishi H, Ohdoi C, Murano H, Ikeda H. Establishment of a tetraploid Meth-A cell line through polyploidization by demecolcine but not by staurosporine, K-252A and paclitaxel. Cell Prolif 2001; 34: 211.
61. Wick MR. Prognostic factors for cutaneous melanoma. Am J Clin Pathol 1998; 110: 713.
62. Gimotty PA, Van Belle P, Elder DE et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses and tumoreginicity in thin invasive cutaneous melanoma. J Clin Oncol 2005; 23: 8048.
63. Heenen M, Thiriar S, Noel JC, Galand P. Ki-67 immunostaining of normal human epidermis. comparison with 3H-thymidine labelling and PCNA immunostaining. Dermatology 1998; 197: 123.
64. Newburger AE, Weinstein G. Cell proliferation patterns in human malignant melanoma in vivo. Cancer 1980; 46: 308.